CME Group Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CME Group Inc. on June 26, 2008, with the earliest event reported on that date. The filing addresses strategic corporate actions regarding licensing agreements and stock exchange listings.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on contractual amendments and listing changes rather than financial performance data.
Material Changes
- License Agreement Amendment: CME, a wholly owned subsidiary, amended its 2003 License Agreement with The NASDAQ OMX Group, Inc. The amendment extends the exclusive license renewal period to December 31, 2019. The Company continues to pay per trade fees to NASDAQ OMX under this agreement.
- Stock Listing Change: The Company announced its intention to list its Class A common stock solely on NASDAQ OMX, effective June 30, 2008. This ends the dual listing on the New York Stock Exchange (NYSE) that has been in place since 2005. Written notification to withdraw from the NYSE was provided on June 30, 2008.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the listing transfer and the license extension. No specific financial guidance, risk factors, or contingencies are detailed in this filing. The full text of the press release regarding the listing change is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the financial impact of the extended exclusive license with NASDAQ OMX through the upcoming Form 10-Q.
- Confirm the effective date of the NYSE delisting and the transition to sole listing on NASDAQ OMX.
- Review the attached press release (Exhibit 99.1) for additional details on the strategic rationale for the listing change.